HC Wainwright & Co. Initiates Coverage On Pyxis Oncology with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has initiated coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and set a price target of $4.

November 30, 2023 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pyxis Oncology received a Buy rating from HC Wainwright & Co. with a price target of $4, indicating a positive outlook from the analyst.
The initiation of coverage by HC Wainwright & Co. with a Buy rating typically generates positive investor sentiment and can lead to an increase in stock price in the short term. The price target of $4 suggests a significant upside potential from the current trading price, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100